Shanghai Fosun Pharmaceutical (Group)'s (HKG:2196) subsidiary S-INFINITY Pharmaceuticals received approval from China's National Medical Products Administration (NMPA) for the clinical trial Phase II of XH-S003 capsules, according to a Thursday filing with the Hong Kong bourse.
XH-S003 is a small molecule inhibitor of the complement system to treat paroxysmal nocturnal hemoglobinuria (PNH).
The Pharmaceutical's shares were up by 4% in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。